This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Anticholinergic drugs used in parkinsonism

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The following anticholinergic drugs may be used to treat parkinsonism:

  • benzhexol hydrochloride - trihexyphenidyl is the recommended International Nonproprietary Name for this drug:
    • initial dose 1 mg daily
    • usual maintenance dose 5-15 mg in 3-4 doses

  • benztropine mesylate:
    • initial dose 0.5 mg daily
    • maximum dose usually 6 mg daily

  • biperiden:
    • initial dose 1 mg twice daily
    • usual maintenance dose 3-12 mg daily in divided doses
    • may be given as an intramuscular or slow intravenous injection

  • orphenadrine hydrochloride:
    • initial dose 150 mg in divived doses
    • maximum dose usually 400 mg daily

  • procyclidine hydrochloride:
    • initial dose 2.5 mg 3 times daily
    • maximum dose usually 30 mg daily
    • may be given by intramuscular injection in acute dystonia

Anticholinergic drugs they should not be used in patients with:

  • untreated urinary retention
  • closed angle glaucoma
  • gastointestinal obstruction

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.